Code intelligence

FDA-NDA221104 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA221104.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: BIXLENVO (BICTEGRAVIR/LENACAPAVIR) — Type 4 - New Combination

Policy FDA-NDA221104 · Infectious Disease

High

BIXLENVO (bictegravir/lenacapavir), an oral tablet combination antiretroviral approved by FDA on August 27, 2026, follows a Part D billing pathway consistent with its oral route of administration. As

View alert

Audit documentation

Building an audit file that includes FDA-NDA221104?

The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

See audit packs — $349One-time purchase · not a subscription